Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Capital Expenditures: 2012-2024

Historic Capital Expenditures for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $332,000.

  • Theravance Biopharma's Capital Expenditures fell 71.94% to $190,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $332,000, marking a year-over-year decrease of 86.66%. This contributed to the annual value of $332,000 for FY2024, which is 86.66% down from last year.
  • As of FY2024, Theravance Biopharma's Capital Expenditures stood at $332,000, which was down 86.66% from $2.5 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Capital Expenditures registered a high of $6.6 million during FY2020, and its lowest value of $332,000 during FY2024.
  • For the 3-year period, Theravance Biopharma's Capital Expenditures averaged around $1.1 million, with its median value being $572,000 (2022).
  • Per our database at Business Quant, Theravance Biopharma's Capital Expenditures spiked by 334.97% in 2023 and then slumped by 86.66% in 2024.
  • Theravance Biopharma's Capital Expenditures (Yearly) stood at $6.6 million in 2020, then plummeted by 48.52% to $3.4 million in 2021, then plummeted by 83.21% to $572,000 in 2022, then surged by 334.97% to $2.5 million in 2023, then tumbled by 86.66% to $332,000 in 2024.